PARIS, Jan. 25, 2011 /PRNewswire/ — Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis (Alternext: ALCLS), has today announced that it will launch gene specific TAL(1) nucleases on February 28, 2011.
Taking advantage of an exclusive license agreement with the University of Minnesota, Cellectis has rapidly integrated TAL effector nucleases into its DNA nuclease production platform. TAL effector nucleases are sequence specific DNA scissors that can be custom engineered to target and modify any gene of interest, in any species. Cellectis is able to produce TAL nucleases in around one week, providing scientists with rapid access to custom-made products.
"This technology has a huge potential and could revolutionize the genome customization world. Being the first to launch TAL nuclease services puts us in an attractive position to gain significant share of the multimillion dollar market for custom DNA nucleases," explained Marc Le Bozec, CEO of Cellectis bioresearch.
"We add yet another asset to our portfolio of important genome customization tools, and invite you to visit our website on February 28, for the official launch of our custom TAL nuclease offer," added Luc Selig, VP Sales and Marketing of Cellectis bioresearch.
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on sequence specific endonucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene function studies. The genome customization products and services can be purchased online from www.cellectis-bioresearch.com.
Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including agriculture, bioresearch and human therapeutics. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris.
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.